## <u>AMENDMENTS TO THE CLAIMS</u>

## In the Claims:

1. (Original) A compound of formula (I):

wherein

X represents O or S;

 $R_1$  represents  $C_{1-6}$  alkyl,  $C_{3-8}$  cycloalkyl,  $C_{3-8}$  cycloalkylmethyl or  $C_{3-8}$  cycloalkenyl any of which optionally may be substituted by one or more methyl groups or halogen atoms or  $R_1$  represents aryl, substituted aryl, heteroaryl or substituted heteroaryl;

 $R_2$  represents hydrogen, methyl, which may be in either the  $\alpha$  or  $\beta$  configuration, or methylene;

R<sub>3</sub> and R<sub>4</sub> are the same or different and each independently represents hydrogen, halogen or a methyl group;

and represents a single or a double bond; or a physiologically acceptable salt or solvate thereof.

- (Original) A compound as claimed in claim 1 wherein X represents O.
- (Previously presented) A compound as claimed in claim 1 wherein R₁ represents a C₃₀ cycloalkyl group optionally substituted by one or more methyl or chlorine groups.
- 4. (Previously presented) A compound as claimed in claim 1 wherein R<sub>1</sub> represents 2,2,3,3-tetramethylcyclopropyl.

Attorney Docket No. P860390USw Application No. 10/564,325

- 5. (Previously presented) A compound as claimed in claim 1 wherein  $R_2$  represents methyl in the  $\alpha$ -configuration.
- 6. (Previously presented) A compound as claimed in claim 1 wherein  $R_3$  and  $R_4$  are both fluorine.
- 7. (Previously presented) A compound as claimed in claim 1 wherein represents a double bond.
- 8. (Previously presented) A compound as claimed in claim 1 which is

 $6\alpha$ , $9\alpha$ -Difluoro-11 $\beta$ -hydroxy-16 $\alpha$ -methyl-3-oxo-17 $\alpha$ -(2,2,3,3-tetramethycyclopropylcarbonyl)oxy-androsta-1,4-diene-17 $\beta$ -carbothloic acid Scyanomethyl ester;

 $17\alpha$ -(4-[(Diethylamino)sulphonyl]benzoyl)oxy-6α,9α-difluoro-11β-hydroxy-16α-methyl-3-oxo-androsta-1,4-diene-17β-carbothioic acid *S*-cyanomethyl ester;

17α-(5-Chloro-4-methoxy-thiophene-3-carbonyl)oxy- $6\alpha$ ,9α-difluoro-11β-hydroxy-16α-methyl -3-oxo-androsta-1,4-diene-17β-carbothioic acid S-cyanomethyl ester;

 $6\alpha$ ,  $9\alpha$ -Diffuoro-11 $\beta$ -hydroxy-16 $\alpha$ -methyl-3-oxo-17 $\alpha$ -(2,2,3,3-tetramethycyclopropylcarbonyl)oxy-androsta-1,4-diene-17 $\beta$ -carboxylic acid cyanomethyl ester;

17α-(Cyclohexylcarbonyl)oxy- $6\alpha$ , $9\alpha$ -difluoro- $11\beta$ -hydroxy- $16\alpha$ -methyl-3-oxo-androsta-1,4-diene- $17\beta$ -carboxylic acid cyanomethyl ester;

 $6\alpha$ ,  $9\alpha$ -Diffuoro- $17\alpha$ -(2,6-diffuorobenzoyl)oxy- $11\beta$ -hydroxy- $16\alpha$ -methyl-3-oxo-androsta-1,4-diene- $17\beta$ -carboxylic acid cyanomethyl ester;

 $6\alpha$ ,  $9\alpha$ -Difluoro-11 $\beta$ -hydroxy-17 $\alpha$ -(4-methoxybenzoyl)oxy-16 $\alpha$ -methyl-3-oxo-androsta-1,4-diene-17 $\beta$ -carboxylic acid cyanomethyl ester;

 $17\alpha$ -(4-Cyanobenzoyl)oxy- $6\alpha$ , $9\alpha$ -difluoro- $11\beta$ -hydroxy- $16\alpha$ -methyl-3-oxo-androsta-1,4-diene- $17\beta$ -carboxylic acid cyanomethyl ester;

17α-(Cyclopentylmethylcarbonyl)oxy- $6\alpha$ , $9\alpha$ -difluoro-11β-hydroxy-16α-methyl-3-oxo-androsta-1,4-diene-17β-carboxylic acid cyanomethyl ester;

 $6\alpha$ ,  $9\alpha$ -Difluoro- $17\alpha$ -(3,3-dimethylbutanoyl) oxy- $11\beta$ -hydroxy- $16\alpha$ -methyl-3-oxo-androsta-1, 4-diene- $17\beta$ -carboxylic acid cyanomethyl ester;

 $6\alpha$ ,  $9\alpha$ -Difluoro-11 $\beta$ -hydroxy-17 $\alpha$ -(2-isopropyl-1,3-thiazole-4-carbonyl)oxy-16 $\alpha$ -methyl-3-oxo-androsta-1,4-diene-17 $\beta$ -carboxylic acid cyanomethyl ester;

6α,9α-Difluoro-11β-hydroxy-16α-methyl-3-oxo-17α-(quinoline-2-carbonyl)oxy-androsta-1,4-diene-17β-carboxylic acid cyanomethyl ester;

 $6\alpha$ ,  $9\alpha$ -Diffuoro-11β-hydroxy-16α-methyl-3-oxo-17α-(5-trifluoromethyl-furan-2-carbonyl)oxy-androsta-1,4-diene-17β-carboxylic acid cyanomethyl ester;

 $6\alpha,9\alpha$ -Difluoro-11 $\beta$ -hydroxy-16 $\alpha$ -methyl -17 $\alpha$ -(5-methylsulphonyl-thiophene-2-carbonyl)oxy-3-oxo-androsta-1,4-diene-17 $\beta$ -carboxylic acid cyanomethyl ester;

 $6\alpha$ ,  $9\alpha$ -Diffuoro-11 $\beta$ -hydroxy-16 $\alpha$ -methyl -17 $\alpha$ -(5-methylthio-thiophene-2-carbonyl)oxy-3-oxo-androsta-1, 4-diene-17 $\beta$ -carboxylic acid cyanomethyl ester;

 $6\alpha$ ,  $9\alpha$ -Difluoro- $17\alpha$ -(5-ethyl-isoxazole-3-carbonyl)oxy- $11\beta$ -hydroxy- $16\alpha$ -methyl-3-oxo-androsta-1,4-diene- $17\beta$ -carboxylic acid cyanomethyl ester;

 $9\alpha$ -Fluoro-11 $\beta$ -hydroxy-16 $\beta$ -methyl-3-oxo-17 $\alpha$ -(2,2,3,3-tetramethylcyclopropylcarbonyl)oxy-androsta-1,4-diene-17 $\beta$ -carboxylic acid cyanomethyl ester;

 $6\alpha$ ,  $9\alpha$ -Difluoro-11 $\beta$ -hydroxy-16 $\alpha$ -methyl-3-oxo-17 $\alpha$ -(2,2,3,3-tetramethycyclopropylcarbonyl)oxy-androst-4-ene-17 $\beta$ -carboxylic acid cyanomethyl ester;

17α-(5-Chloro-4-methoxy-thiophene-3-carbonyl)oxy-6α,9α-difluoro-11β-hydroxy-16α-methyl -3-oxo-androsta-1,4-diene-17β-carboxylic acid cyanomethyl ester;

17α-(2,2-Dichloro-3,3-dimethylclopropylcarbonyl)oxy- $6\alpha$ ,9α-difluoro-11β-hydroxy-16α-methyl-3-oxo-androsta-1,4-diene-17β-carboxylic acid cyanomethyl ester;

 $17\alpha$ -(2,2-Dichloro-3,3-dimethylclopropylcarbonyl)oxy- $6\alpha$ ,9α-difluoro- $11\beta$ -hydroxy- $16\alpha$ -methyl-3-oxo-androsta-1,4-diene- $17\beta$ -carbothioic acid S-cyanomethyl ester;

17α-(Cyclohexylcarbonyl)oxy- $6\alpha$ ,9α-difluoro-11β-hydroxy-16α-methyl-3-oxo-androsta-1,4-diene-17β-carbothioic acid S-cyanomethyl ester;

6α,9α-Difluoro-11β-hydroxy-16α-methyl -17α-(5-methylsulphonyl-thiophene-2-carbonyl)oxy-3-oxo-androsta-1,4-diene-17β-carbothioic acid S- cyanomethyl ester;

 $6\alpha$ , $9\alpha$ -Difluoro-11 $\beta$ -hydroxy-16 $\alpha$ -methyl-3-oxo-17 $\alpha$ -(5-trifluoromethyl-furan-2-carbonyl)oxy-androsta-1,4-diene-17 $\beta$ -carbothioic acid S-cyanomethyl ester; or

 $6\alpha$ ,  $9\alpha$ -Diffuoro- $17\alpha$ -(3-(diffuoromethylthio)benzoyl)oxy- $11\beta$ -hydroxy- $16\alpha$ -methyl-3-oxo-androsta-1,4-diene- $17\beta$ -carbothioic acid S-cyanomethyl ester.

9. (Original) A compound as claimed in claim 8 which is

 $6\alpha$ , $9\alpha$ -Difluoro-11 $\beta$ -hydroxy-16 $\alpha$ -methyl-3-oxo-17 $\alpha$ -(2,2,3,3-tetramethycyclopropylcarbonyl)oxy-androsta-1,4-diene-17 $\beta$ -carbothioic acid S-cyanomethyl ester;

 $6\alpha$ , $9\alpha$ -Difluoro-11 $\beta$ -hydroxy-16 $\alpha$ -methyl-3-oxo-17 $\alpha$ -(2,2,3,3-tetramethycyclopropylcarbonyl)oxy-androsta-1,4-diene-17 $\beta$ -carboxylic acid cyanomethyl ester:

 $9\alpha$ -Fluoro-11β-hydroxy-16β-methyl-3-oxo-17α-(2,2,3,3-tetramethylcyclopropylcarbonyl)oxy-androsta-1,4-diene-17β-carboxylic acid cyanomethyl ester;

 $17\alpha$ -(Cyclohexylcarbonyl)oxy- $6\alpha$ , $9\alpha$ -difluoro- $11\beta$ -hydroxy- $16\alpha$ -methyl-3-oxo-androsta-1,4-diene- $17\beta$ -carboxylic acid cyanomethyl ester;

 $17\alpha$ -(Cyclopentylmethylcarbonyl)oxy- $6\alpha$ , $9\alpha$ -difluoro- $11\beta$ -hydroxy- $16\alpha$ -methyl-3-oxo-androsta-1,4-diene- $17\beta$ -carboxylic acid cyanomethyl ester;

6α,9α-Difluoro-17α-(3,3-dimethylbutanoyl)oxy-11β-hydroxy-16α-methyl-3-oxo-androsta-1,4-diene-17β-carboxylic acid cyanomethyl ester;

 $6\alpha$ ,  $9\alpha$ -Difluoro- $17\alpha$ -(3-(difluoromethylthio)benzoyl)oxy- $11\beta$ -hydroxy- $16\alpha$ -methyl-3-oxo-androsta-1,4-diene- $17\beta$ -carbothioic acid S-cyanomethyl ester;

17α-(Cyclohexylcarbonyl)oxy-6α,9α-difluoro-11β-hydroxy-16α-methyl-3-oxo-androsta-1,4-diene-17β-carbothioic acid S-cyanomethyl ester;

 $6\alpha$ ,  $9\alpha$ -Difluoro- $17\alpha$ -(5-ethyl-isoxazole-3-carbonyl)oxy- $11\beta$ -hydroxy- $16\alpha$ -methyl-3-oxo-androsta-1,4-diene- $17\beta$ -carboxylic acid cyanomethyl ester;

 $6\alpha$ ,  $9\alpha$ -Difluoro-11β-hydroxy-16 $\alpha$ -methyl -17 $\alpha$ -(5-methylthio-thiophene-2-carbonyl)oxy-3-oxo-androsta-1,4-diene-17β-carboxylic acid cyanomethyl ester;

 $6\alpha$ ,  $9\alpha$ -Diffuoro-11 $\beta$ -hydroxy-17 $\alpha$ -(2-isopropyl-1,3-thiazole-4-carbonyl)oxy-16 $\alpha$ -methyl-3-oxo-androsta-1,4-diene-17 $\beta$ -carboxylic acid cyanomethyl ester;

 $17\alpha$ -(2,2-Dichloro-3,3-dimethylclopropylcarbonyl)oxy- $6\alpha$ ,9α-diffuoro- $11\beta$ -hydroxy- $16\alpha$ -methyl-3-oxo-androsta-1,4-diene- $17\beta$ -carbothioic acid S-cyanomethyl ester; or

 $17\alpha$ -(2,2-Dichloro-3,3-dimethylclopropylcarbonyl)oxy- $6\alpha$ , $9\alpha$ -difluoro- $11\beta$ -hydroxy- $16\alpha$ -methyl-3-oxo-androsta-1,4-diene- $17\beta$ -carboxylic acid cyanomethyl ester.

10. (Currently amended) A compound as claimed in claim 9 which is

 $17\alpha$ -(2,2-Dichloro-3,3-dimethylclopropylcarbonyl)oxy- $6\alpha$ ,9α-diffuoro- $11\beta$ -hydroxy- $16\alpha$ -methyl-3-oxo-androsta-1,4-diene- $17\beta$ -carboxylic acid cyanomethyl ester;

 $6\alpha$ ,9α-Difluoro-11β-hydroxy-16α-methyl-3-oxo-17α-(2,2,3,3-tetramethycyclopropylcarbonyl)oxy-androsta-1,4-diene-17β-carbothioic acid Scyanomethyl ester; or

 $6\alpha$ , $9\alpha$ -Difluoro-11 $\beta$ -hydroxy-16 $\alpha$ -methyl-3-oxo-17 $\alpha$ -(2,2,3,3-tetramethycyclopropylcarbonyl)oxy-androsta-1,4-diene-17 $\beta$ -carboxylic acid cyanomethyl ester.

11. (Original) A compound as claimed in claim 10 which is

 $6\alpha,9\alpha$ -Difluoro-11 $\beta$ -hydroxy-16 $\alpha$ -methyl-3-oxo-17 $\alpha$ -(2,2,3,3-tetramethycyclopropylcarbonyl)oxy-androsta-1,4-diene-17 $\beta$ -carboxylic acid cyanomethyl ester.

12-13. (Cancelled)

14. (Currently amended) A pharmaceutical composition comprising a compound of formula (I) as defined in claim 1 or a physiologically acceptable solvate thereof together, if desirable, in admixture with one or more physiologically acceptable diluents or carriers.

- 15. (Previously presented) A pharmaceutical aerosol formulation comprising a compound of formula (I) as defined in claim 1 or a physiologically acceptable solvate thereof, and a fluorocarbon or hydrogen-containing chlorofluoro carbon as propellant, optionally in combination with a surfactant and/or a cosolvent.
- 16. (Currently amended) A pharmaceutical composition according to claim 15 which further comprises another one or more therapeutically active agents.
- 17. (Currently amended) A pharmaceutical composition according to claim 16 in which said another one or more therapeutically active agents is a  $\beta_2$ -adrenoreceptor agonist.
- 18. (Currently amended) A method for the treatment of a human or animal subject with an anti-inflammatory inflammatory and/or allergic condition, which method comprises administering to said human or animal subject an effective amount of a compound of formula (I) as defined in claim 1 or a physiologically acceptable solvate thereof.

19-20. (Cancelled)

21. (Currently amended) A process for preparing a compound of formula (II)

where R<sub>1</sub> represents 2,2,3,3 – tetramethyl cyclopropyl and R<sub>2</sub>, R<sub>3</sub>, R<sub>4</sub>, X and are as defined in claim 1 which process comprises reaction of the 1,2-dimethyl-1*H*-imidazolium ester of 2,2,3,3-tetramethylcyclopropane carboxylic acid (IV)

with the corresponding 17a-hydroxyl derivative of formula (III)

22. (Original) A process as claimed in claim 21 in which X represents O.